Summary
BACKGROUND The coronavirus disease 2019 (COVID-19) is a newly emerged infection from the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Apart from the respiratory system, it is unclear whether SARS-CoV-2 can also directly infect other tissues such as the kidney or induce acute renal failure.
METHODS We conducted a retrospective analysis of estimated glomerular filtration rate (eGFR), plasma creatinine, and urea concentrations along with other clinical parameters from 85 patients with laboratory-confirmed COVID-19 admitted to a hospital in Wuhan from January 17, 2020 to March 3, 2020. Kidney tissues from six other patients with postmortem examinations were analyzed by Hematoxylin and Eosin (H&E) and in situ expression of viral nucleocaspid protein (NP) antigen was detected by immunohistochemistry.
RESULTS Among these 85 COVID-19 patients, 27.06% (23/85) COVID-19 patients exhibited acute renal failure (ARF), and elder patients (≥ 60 years old) are easier to develop ARF (65.22% vs 24.19%, p< 0.001). Comorbidities of disorders like hypertension and heart failure were more common in patients who developed ARF (69.57% vs 11.29%, p< 0.001). Dynamic observation of eGFR revealed that perished cases have a rapid decrease of eGFR but quickly boosting plasma creatinine and urea. On the other hand, enhancement of eGFR and persistence low level of plasma creatinine and urea was observed in recovery patients following diuretic treatment. H&E staining demonstrated kidney tissues from 6 cases of postmortems have severe acute tubular necrosis but no evidence of glomerular pathology. Immunohistochemistry showed that SARS-CoV-2 NP antigen was accumulated in kidney tubules.
CONCLUSIONS The development of ARF during the course of disease is an important negative prognostic indicator for survival with COVID-19. SARS-CoV-2 virus directly infects human kidney tubules by thus induces acute tubular damage ARF and probably also lead to urine transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funding agencies did not participate in study design, data collection, data analysis, or manuscript writing.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
For protection of patients' privacy, all data used during the study are only be provided with anonymized version.
